Enterprise Value

0.00

Cash

52.2M

Avg Qtr Burn

N/A

Short % of Float

0.05%

Insider Ownership

61.26%

Institutional Own.

0.77%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ryplazim® (plasminogen) Details
Congenital Plasminogen Deficiency (C-PLGD)

Approved

Quarterly sales

LMNL6511 (GPR84 receptor) Details
Idiopathic pulmonary fibrosis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic steatohepatitis , Metabolic disorder

Phase 1

Update

Failed

Discontinued

Fezagepras (PBI-4050) Details
Rare diseases, Lung disease

Failed

Discontinued

Fezagepras (PBI-4050) Details
Rare diseases, Rare genetic disease

Failed

Discontinued